Sharps Technology (STSS) - Pangali EV/EBITDA

Sharps Technology, Inc. (STSS) faces intense pressure from industry behemoths and challenges in expanding sales. Meanwhile, the company is introducing unique syringes that prevent accidental injuries and the reuse of needles. The EV/EBITDA multiples shown below, valued at 0.00, illustrate the market position of a brand striving to displace outdated budget consumables through technological superiority.

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest. Daily monitoring allows investors to filter out market noise and accurately identify the moment financial stability is compromised. By analyzing the historical EV/EBITDA trend of a company, an investor can discern the business's actual ability to service its debt. For Sharps Technology, Inc. (STSS), this is critical when scaling injection systems amid intense pressure from medtech behemoths.